Guihong Lu

Guihong Lu

Auto-generated profile, based on publicly available information

Guihong Lu

Institute of Pediatrics Shenzhen Children's Hospital Affiliated Shenzhen Children's Hospital of Shantou University Medical College Shenzhen People's Republic of China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
GLGuihong Lu
Guihong Lu
XWXiaojun Wang
Xiaojun Wang
FLFeng Li
Feng Li
SWShuang Wang
Shuang Wang
JZJiawei Zhao
Jiawei Zhao
WWWei Wei
Wei Wei
Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. Here, building on the observation of elevated lactate (LA) in resected GBM, we develop biomimetic therapeutic nanoparticles (NPs) that deliver agents for LA metabolism-based synergistic therapy. Because our self-assembling NPs are encapsulated in membranes derived from glioma cells, they readily penetrate the blood-brain barrier and target GBM through homotypic recognition. After reaching the tumors, lactate oxidase in the NPs converts LA into pyruvic acid (PA) and hydrogen peroxide (H2O2). The PA inhibits cancer cell growth by blocking histones expression and inducing cell-cycle arrest. In parallel, the H2O2 reacts with the delivered bis[2,4,5-trichloro-6-(pentyloxycarbonyl)phenyl] oxalate to release energy, which is used by the co-delivered photosensitizer chlorin e6 for the generation of cytotoxic singlet oxygen to kill glioma cells. Such a synergism ensures strong therapeutic effects against both glioma cell-line derived and patient-derived xenograft models.

19 June 2018 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
XXXiaobo Xi
Xiaobo Xi
LZLijun Zhang
Lijun Zhang
GLGuihong Lu
Guihong Lu
XGXiaoyong Gao
Xiaoyong Gao
WWWei Wei
Wei Wei
Guanghui MaGuanghui Ma
Guanghui Ma
Therapeutic vaccines that arouse the cytotoxic T cell immune response to reject infected cells have been investigated extensively for treating disease. Due to the large amounts of resident antigen-presenting cells (APCs) and T cells in lymph nodes, great efforts have been made to explore the strategy of targeting lymph nodes directly with nanovaccines to activate T cells. However, these nanovaccines still have several problems, such as a low loading efficiency and compromised activity of antigens and adjuvants derived from traditional complicated preparation. There are also safety concerns about materials synthesized without FDA approval. Herein, we construct an assembled nanoparticle composed of an antigen (ovalbumin, OVA) and adjuvant (CpG) to ensure its safety and high loading efficiency. The activity of both components was well preserved due to the mild self-assembly process. The small size, narrow distribution, negative charge, and good stability of the nanoparticle endow these nanovaccines with superior capacity for lymph node targeting. Correspondingly, the accumulation at lymph nodes can be improved by 10-fold. Subsequently, due to the sufficient APC internalization and maturation in lymph nodes, ~60% of T cells are stimulated to proliferate and over 70% of target cells are specifically killed. Based on the effective and quick cellular immune response, the assembled nanoparticles exhibit great potential as therapeutic vaccines.

23 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
CLChengliang Lyu
Chengliang Lyu
ZHZhanlong He
Zhanlong He
XHXiaoming Hu
Xiaoming Hu
SWShuang Wang
Shuang Wang
MQMeng Qin
Meng Qin
WWWei Wei
Wei Wei
The binding of viruses to host-entry factor receptors is an essential step for viral infection. Many studies have shown that macrophages can internalize viruses and degrade them in lysosomes for clearance in vivo. Inspired by these natural behaviors and using SARS-CoV-2 as a testbed, we harvest lysosomes from activated macrophages and anchor the protein-receptor ACE2 as bait, thus constructing a lysosomal “TRAP” (lysoTRAP) that selectively captures, internalizes, and eventually degrades SARS-CoV-2. Through experiments with cells, female mice, female hamsters, and human lung organoids, we demonstrate that lysoTRAP effectively clears SARS-CoV-2. Importantly, unlike therapeutic agents targeting SARS-CoV-2 spike protein, lysoTRAP remains effective against nine pseudotyped variants and the authentic Omicron variant, demonstrating its resistance to SARS-CoV-2 mutations. In addition to the protein-receptor ACE2, we also extend lysoTRAP with the saccharide-receptor sialic acid and verify its excellent antiviral effect against H1N1, highlighting the flexibility of our “TRAP” platform in fighting against various viruses.

2 August 2026 in BMEMat
Verified
Journal Article
Open access
PDF file
GLGuihong Lu
Guihong Lu
PYPeng Ye
Peng Ye
XLXiaoyan Li
Xiaoyan Li
KMKe Ma
Ke Ma
CLChengliang Lyu
Chengliang Lyu
HTHui Tan
Hui Tan
Stimuli‐responsive nanomaterials hold great promise for precision cancer therapy; however, achieving spatiotemporal control over therapeutic activation remains a formidable challenge due to premature release, insufficient tumor specificity, and limited responsiveness to endogenous cues. Herein, we report a programmable nanocomposite featuring a three‐state transformation mechanism—resting, activated, and burst states—for controllable and efficient tumor treatment. The nanocomposite was constructed by coating the bacterial outer membrane vesicle (OMV) with a biocompatible dopamine–calcium carbonate (Da–Ca) shell, forming a stable structure under physiological conditions (resting state). Upon accumulation in the mildly acidic tumor microenvironment, the system transitions into an activated state, where internal destabilization occurs without disrupting the shell morphology. Subsequent near‐infrared (NIR) laser irradiation triggers a rapid transition to the burst state, resulting in complete shell disintegration and the synchronous release of OMVs and calcium ions. This cascade‐like activation enables synergistic photothermal therapy, calcium overload‐induced cytotoxicity, and immunotherapy via OMV‐mediated immune activation. The programmable nature of the system ensures precise tumor targeting, minimized systemic toxicity, and robust antitumor efficacy. This work provides a versatile platform for next‐generation nanotherapeutics with enhanced safety and multimodal therapeutic integration.

15 October 2026 in Advanced Science
Verified
Journal Article
Open access
XLXing Liu
Xing Liu
JZJiaxin Zhou
Jiaxin Zhou
GLGuihong Lu
Guihong Lu
CZChenjing Zhao
Chenjing Zhao
WWWeixiu Wang
Weixiu Wang
WNWeidong Nie
Weidong Nie
Cold tumors evade APC and T‐cell surveillance through low immunogenicity, defective antigen presentation, and immunosuppressive tumor microenvironments. We uncovered a non‐canonical function of bacterial outer membrane vesicles (OMVs), whereby OMVs activated the TLR4–NF‐κB–NLRC5 axis to induce tumor MHC I upregulation, thereby restoring tumor visibility to T cells. To further eliminate tumor invisibility to APCs, we reported a bacteria‐inspired strategy that drives APCs to perceive tumor cells as bacteria. By fusing OMVs with fusogenic liposomes, we constructed fusogenic OMVs (FOs) that anchor bacterial membrane components onto tumor surfaces, thereby functionally “bacterizing” tumor cells. This modification markedly increased APC recruitment and effectively reprogrammed APC perception from silent tumor clearance to active microbial‐like immune surveillance. Consequently, APCs exhibited enhanced phagocytic uptake of bacterized tumors, enabling efficient cross‐presentation of the tumor‐antigen repertoires to T cells. Concurrently, OMVs upregulated MHC I expression on tumor cells, which strengthened effector T cell recognition and cytotoxicity toward tumors. Furthermore, by loading 3‐bromopyruvate into the vesicles, we endowed the system with metabolic reprogramming capability, characterized by glycolysis suppression and lactate depletion. Together, the synergistic immune–metabolic modulation resulted in durable suppression of tumor progression following intratumoral administration, offering a bacterization‐inspired nanoplatform to overcome key immunological barriers in immune‐cold tumors.

21 September 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
CLChengliang Lyu
Chengliang Lyu
ZHZhanlong He
Zhanlong He
XHXiaoming Hu
Xiaoming Hu
SWShuang Wang
Shuang Wang
MQMeng Qin
Meng Qin
WWWei Wei
Wei Wei